Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 4/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31051044 | 1.00 | DHODH (0.50) | DHODHCYP11B2MAOAMAOBNAPRT | |
| SCHEMBL3881160 | 0.84 | CYP11B2 (0.50) | DHODHCYP11B2MAOAMAOBNAPRT | |
| SCHEMBL2489325 | 0.84 | MAPT (0.49) | DHODHCYP11B2MAOAMAOBNAPRT | |
| SCHEMBL29889660 | 0.84 | MAPT (0.49) | DHODHCYP11B2MAOAMAOBNAPRT | |
| SCHEMBL2876757 | 0.83 | GSTP1 (0.49) | DHODHCYP11B2GRM5NISCHCYP11B1 | |
| SCHEMBL24196449 | 0.81 | CYP11B2 (0.47) | DHODHCYP11B2MAOAMAOBNAPRT | |
| SCHEMBL12947927 | 0.81 | DHODH (0.48) | DHODHCYP11B2MAOAMAOBMAPT | |
| SCHEMBL18255779 | 0.81 | CYP11B2 (0.47) | DHODHCYP11B2MAOAMAOBMAPT | |
| SCHEMBL22230844 | 0.81 | CYP11B2 (0.47) | DHODHCYP11B2MAOAMAOBNAPRT | |
| SCHEMBL29889779 | 0.81 | CYP2A6 (0.55) | CYP11B2MAPTALDH1A1HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262803-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chungdu Anticancer Bioscience Ltd (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20230155173-A1 | ELECTROLYTE AND ELECTROCHEMICAL DEVICE USING THE SAME | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230155173-A1 | ELECTROLYTE AND ELECTROCHEMICAL DEVICE USING THE SAME | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2023-05-18 | — | — | US | disclosed |
| WO-2022199654-A1 | HETEROARYL-HETEROARYL-O-PHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2022-09-29 | — | — | WO | disclosed |
| US-7488728-B2 | Pyridinylmorpholine derivatives | ELI LILLY AND COMPANY (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| CN-1889940-A | Treatment of personality changes due to hot flashes, impulse control disorders and systemic medical conditions | LILLY CO ELI (US) | 2007-01-03 | — | — | CN | disclosed |
| EP-1729754-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1660185-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1658287-A1 | PYRIDINYLMORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005060949-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005053663-A2 | NOREPINEPHRINE REUPTAKE INHIBITORS USEFUL FOR TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005023802-A1 | PYRIDINYLMORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021095-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-5779935-A | HAVING REDUCED CONE ANGLE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | disclosed |
| US-5695683-A | Ferroelectric liquid crystal mixture | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | DHODH 691/4885CYP11B2 2864/4885MAOA 16/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | DHODH 1383/4885CYP11B2 2124/4885MAOA 36/4885 |
| US-20240262803-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | DHODH 1245/4885CYP11B2 26/4885MAOA 881/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | DHODH 1529/4885CYP11B2 1024/4885MAOA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.